NewsBenzingaMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57 Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57 Benzinga 2026.09.23 11:36 (GMT+0) Open on Benzinga Other news Samsung to Support KT and SK Telecom on South Korea's AI RAN Project Founders Fund and Other US VCs Recently Made Intensive Visits to China to Inspect AI Companies Is KeyCorp Stock Underperforming the S&P 500? MoonPay to acquire North Capital for over $60 million, eyeing tokenized securities LinkedIn adds new tools to fight fake profiles and bogus work histories Spotify’s is giving you the keys to its recommendation algorithm with US launch of ‘Taste Profile’
